Breaking News, Financial News

Financial Report: Covance

Late-Stage Development revenues up 13%

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Covance   2Q Revenues: $585.0 million (+7%) 2Q Loss: $12.7 million (earnings were $37.6 million 2Q11) YTD Revenues: $1.2 billion (+8%) YTD Earnings: $23.0 million (-67%) Comments: Early Development revenues in the quarter were down 5% to $219.7 million. Late-Stage Development revenues were up 13% to $323.1 million. Backlog at June 30, 2012 was $6.2 billion compared to $6.3 billion at June 30, 2011. Foreign exchange negatively impacted backlog by $105 million. Expenses totaled $38.9 million i...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters